VNDA - Biotech Stock Roundup: IRON VERV Down on Study Updates BMYs Drug News & More | Benzinga
Pipeline and regulatory updates continue to be in focus in the biotech sector. While nothing much came out of bigwigs apart from a few, shares of clinical-stage biotechs like Disc Medicine, Inc. (NASDAQ: IRON) and Verve Therapeutics (NASDAQ: VERV) plunged on disappointing updates.
Recap of the Week's Most Important Stories:
Updates From BMY: Bristol Myers Squibb (NYSE: BMY) announced that the European Commission has approved a label expansion of Reblozyl (luspatercept). The EC expanded the drug's label to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). The approval of Reblozyl covers all European Union (ETF:EU) member states.
The latest approval is based on results of the late-stage COMMANDS study, wherein Reblozyl demonstrated superior efficacy compared to epoetin alfa in the study's primary endpoint of concurrent red blood cell transfusion independence and hemoglobin increase.
Safety results were consistent with previous MDS studies and in line with expected symptoms in this patient population. Reblozyl is already indicated in the EU for the treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk MDS with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. It is also indicated for the treatment of adult patients with anemia, associated with transfusion-dependent and non-transfusion-dependent beta-thalassemia.
Earlier, Bristol Myers announced that a late-stage study on orally-administered Zeposia (ozanimod) in Crohn's disease (CD) indication failed to achieve its primary endpoint. This late-stage study was the first of the two induction studies in the phase III YELLOWSTONE clinical program, which evaluated Zeposia in 600 adult patients with moderate to severe active CD over a 12-week treatment period. Initial results from the study showed that treatment with Zeposia failed to meet the primary endpoint of clinical remission at week 12.
BMY currently has a Zacks Rank #3 (Hold).
IRON Down on Study Results: Shares of ...